Quantbot Technologies LP Takes Position in Edwards Lifesciences Corporation $EW

Quantbot Technologies LP purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 362 shares of the medical research company’s stock, valued at approximately $26,000.

A number of other large investors have also made changes to their positions in the stock. Korea Investment CORP increased its holdings in shares of Edwards Lifesciences by 37.5% in the 1st quarter. Korea Investment CORP now owns 647,275 shares of the medical research company’s stock valued at $46,914,000 after purchasing an additional 176,625 shares in the last quarter. Aptus Capital Advisors LLC increased its holdings in shares of Edwards Lifesciences by 3.8% in the 1st quarter. Aptus Capital Advisors LLC now owns 10,386 shares of the medical research company’s stock valued at $753,000 after purchasing an additional 385 shares in the last quarter. Watts Gwilliam & Co. LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $210,000. Granite Harbor Advisors Inc. increased its holdings in shares of Edwards Lifesciences by 10.2% in the 1st quarter. Granite Harbor Advisors Inc. now owns 4,989 shares of the medical research company’s stock valued at $362,000 after purchasing an additional 462 shares in the last quarter. Finally, Versor Investments LP purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $1,123,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $81.48 on Friday. The company has a market cap of $47.84 billion, a PE ratio of 11.72, a price-to-earnings-growth ratio of 3.92 and a beta of 1.08. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a 50-day simple moving average of $78.31 and a 200-day simple moving average of $75.02.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,584 shares of company stock worth $1,897,762 over the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Piper Sandler increased their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 25th. The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Citigroup restated a “buy” rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, Morgan Stanley raised their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.